How Much Does Belsomra Cost in Texas in 2026?

The Cash Price Breakdown Across Texas Pharmacies

A 30-day supply of brand-name Belsomra has a wholesale acquisition cost (WAC) of $340, but that number almost never reflects what patients actually hand over at the counter. Across Texas retail pharmacies in 2026, the average cash-pay price sits around $85 per month after discount card and coupon programs are factored in.

Prices vary by pharmacy chain and zip code. Large-volume retailers in Houston and Dallas-Fort Worth metros tend to price lower than independent pharmacies in rural West Texas, sometimes by $15 to $25 per fill. GoodRx-type aggregator pricing for suvorexant 20 mg (30 tablets) in Austin, San Antonio, and El Paso clusters between $75 and $100 at most major chains as of early 2026.

The FDA approved suvorexant in 2014 as the first dual orexin receptor antagonist (DORA) for insomnia characterized by difficulty with sleep onset and sleep maintenance [1]. The Herring et al. trial published in The Lancet Neurology (N=3,076 across two Phase III studies) demonstrated that suvorexant 20 mg reduced subjective time to sleep onset by approximately 10 minutes more than placebo and increased total sleep time by roughly 16 to 25 minutes at 3 months [2]. Those effect sizes inform every insurer's cost-effectiveness calculation, and they explain why prior authorization remains common.

Patients paying out of pocket should ask the dispensing pharmacist to run the prescription through multiple discount programs before accepting the first quoted price. A single pharmacy can return different totals depending on which card is applied.

Texas Medicaid Does Not Cover Belsomra for Insomnia

This is the single biggest coverage gap for low-income Texans with sleep disorders. Texas Medicaid's Vendor Drug Program does not include Belsomra on its preferred drug list for insomnia. The formulary restricts suvorexant to narrow use cases tied to Type 2 diabetes comorbidity lines, effectively locking out patients whose sole indication is chronic insomnia disorder.

Texas Medicaid managed care organizations (MCOs) like Superior HealthPlan, Molina, and UnitedHealthcare Community Plan follow the state's Vendor Drug Program restrictions. A prescriber can submit a prior authorization request, but approvals for insomnia-only diagnoses are rare. The American Academy of Sleep Medicine's 2017 clinical practice guideline lists suvorexant as an option for sleep-maintenance insomnia [3], yet state Medicaid committees weigh budget impact heavily.

For Medicaid-enrolled patients, the practical alternatives are generic trazodone (often $4 to $10 per month), generic zolpidem ($8 to $15 per month), or referral to cognitive behavioral therapy for insomnia (CBT-I), which the AASM rates as first-line treatment [3]. A Medicaid beneficiary who has failed these alternatives and has documented contraindications may have slightly better odds on appeal, but the path is narrow.

Commercial Insurance: Tier Placement and Prior Authorization

Most Texas-based commercial plans from Blue Cross Blue Shield of Texas, Aetna, Cigna, and UnitedHealthcare place Belsomra on Tier 3 (preferred brand) or Tier 4 (non-preferred brand). Tier 3 copays typically range from $40 to $75; Tier 4 copays can reach $80 to $130, depending on the plan's cost-sharing structure.

Prior authorization is nearly universal. Insurers require documentation that the patient has tried and failed at least one first-line agent (usually zolpidem or eszopiclone) and that non-pharmacologic therapy such as CBT-I has been considered. Some plans add a step-therapy edit requiring failure of two generic sleep agents before they authorize Belsomra.

The Endocrine Society and ACP have not issued specific guidance on suvorexant cost-effectiveness, but the Institute for Clinical and Economic Review (ICER) has noted that DORAs carry a higher per-QALY cost than generic alternatives [4]. That analysis drives many formulary committees to gate access behind step therapy.

Texas employers with self-funded plans (common among large oil-and-gas and technology companies in Houston and Austin) sometimes negotiate more favorable DORA coverage. Employees on these plans should check their Summary of Benefits or call the pharmacy benefit manager directly.

How the Merck Savings Card Works in Texas

Merck offers a manufacturer copay card for commercially insured patients that can reduce the out-of-pocket cost to as low as $0 per 30-day fill, subject to annual and per-fill caps. The program is available to patients with commercial insurance only. It does not apply to prescriptions paid through Medicare Part D, Medicaid, TRICARE, or any other government-funded program.

To activate the card, patients visit the Belsomra savings program website, answer eligibility questions, and receive a digital or physical card. The card is presented at the pharmacy alongside the patient's insurance card. The savings card covers the gap between the insurer's allowed copay and the patient's actual cost, up to a set maximum (historically around $75 per fill, though Merck adjusts this periodically).

Texas pharmacists process the card as a secondary claim. One common issue: if the pharmacy runs the discount card instead of insurance rather than after insurance, the savings can be reduced. Patients should confirm with the pharmacist that the primary insurance claim processes first.

The savings card has a 12-month enrollment cycle. Patients must re-enroll annually. For 2026, the program remains active, but terms can change at any time. The FDA label for Belsomra lists the full prescribing information, including approved indications and dosing parameters [5].

Compounded Suvorexant: Legal in Texas Under 503A Rules

Compounded suvorexant is available through Texas-licensed 503A pharmacies. The Texas State Board of Pharmacy permits compounding of commercially available drugs when a prescriber documents a patient-specific clinical need, such as an allergy to an inactive ingredient in the brand product, a need for an alternative dose form, or a pediatric dosing requirement.

Texas compounding regulations follow both federal DQSA (Drug Quality and Security Act) requirements and state-level Board of Pharmacy rules under Title 22, Texas Administrative Code, Chapter 291. A 503A pharmacy must compound pursuant to a valid, patient-specific prescription. Batch compounding without individual prescriptions falls under 503B (outsourcing facility) rules and requires FDA registration.

Pricing for compounded suvorexant in Texas varies widely. Some 503A pharmacies offer compounded formulations at significantly lower cost than the brand product, while others price closer to retail. Patients should request a quote directly from the compounding pharmacy and confirm that the pharmacy holds a current Texas compounding license.

The clinical consideration with compounded suvorexant is bioequivalence. Compounded preparations are not FDA-approved and do not undergo the same dissolution and bioavailability testing as the brand tablet. The prescriber and patient should discuss this distinction. The FDA has issued guidance documents noting that compounded drugs are not evaluated for safety, efficacy, or manufacturing quality to the same standard as approved products [6].

Telehealth Access to Belsomra in Texas

Texas allows prescribing of Belsomra via telehealth. Suvorexant is a Schedule IV controlled substance under federal and Texas law, and after the DEA's 2025 telemedicine prescribing rules, clinicians can prescribe Schedule III through V substances via audio-video telehealth visits without a prior in-person exam, provided the platform meets DEA registration and state licensing requirements [7].

Texas Medical Board rules require that the prescribing physician hold an active Texas medical license. The physician-patient relationship can be established via a synchronous audio-video encounter. Audio-only (phone-only) encounters for initial controlled substance prescriptions remain restricted under Texas law, though follow-up refills may be handled by phone at the prescriber's discretion.

Multiple telehealth platforms operating in Texas offer insomnia consultations. Pricing for the telehealth visit itself ranges from $50 to $150 for an initial consultation. The prescription is sent electronically to the patient's preferred Texas pharmacy. Patients should verify that the platform's prescribing clinicians hold Texas licenses and that the prescription will be transmitted via EPCS (Electronic Prescribing for Controlled Substances).

Comparing Suvorexant to Other Texas-Available Sleep Medications

Generic zolpidem (Ambien) costs $8 to $15 per month cash-pay in Texas and is covered by virtually every insurance plan and Medicaid. It works through a different mechanism (GABA-A receptor modulation) and carries different side-effect concerns, including next-morning impairment and complex sleep behaviors [8].

Lemborexant (Dayvigo), the other DORA approved by the FDA, runs approximately $350 to $400 per month at list price, with cash-pay pricing in Texas around $90 to $110. Its formulary placement is similar to Belsomra's. The Kärppä et al. head-to-head trial (SUNRISE-2, N=949) compared lemborexant 5 mg and 10 mg against placebo over 12 months and demonstrated sustained efficacy, but did not directly compare to suvorexant [9].

Low-dose doxepin (Silenor) is available generically for $15 to $30 per month and targets histamine receptors. Trazodone, used off-label, costs $4 to $10 per month. The AASM guideline conditionally recommends suvorexant for sleep-maintenance insomnia but ranks CBT-I as the first-line intervention for chronic insomnia in all adults [3].

For a Texas patient choosing between these options, the decision matrix involves cost, insurance coverage, clinical profile (onset vs. maintenance insomnia), and prior medication trials. A prescriber familiar with the patient's history is the right person to weigh these factors.

Saving Money on Belsomra in Texas: A Practical Checklist

Start with insurance. Run a formulary check and ask whether prior authorization has a reasonable approval path given the patient's medication history. If the insurer covers Belsomra, apply the Merck savings card as secondary to reduce the copay further.

If uninsured or underinsured, compare cash prices across at least three Texas pharmacies using a discount aggregator. Costco pharmacies (no membership required for pharmacy in Texas) and H-E-B pharmacies frequently post competitive pricing on brand-name medications.

Ask the prescriber whether a 10 mg dose (the recommended starting dose per the FDA label) is appropriate. Suvorexant is available in 5 mg, 10 mg, 15 mg, and 20 mg tablets, and all strengths are priced identically per tablet at most pharmacies. Starting at 10 mg avoids the need to escalate quickly and may stretch a 30-day supply if the patient responds at the lower dose.

For patients with a documented clinical need for a non-standard formulation, a licensed Texas 503A compounding pharmacy may offer a lower-cost alternative. Discuss this option with both the prescriber and the pharmacist.

Patient assistance programs beyond the Merck savings card include NeedyMeds and RxAssist, which aggregate manufacturer and foundation programs. Merck's own patient assistance program (Merck Helps) provides free medication to qualifying uninsured patients with household incomes below 400% of the federal poverty level [10].

The federal 340B Drug Pricing Program covers certain Texas safety-net providers (federally qualified health centers, disproportionate-share hospitals). Patients receiving care at a 340B-eligible facility may access Belsomra at significantly reduced cost.

Dr. Andrew Krystal, a psychiatrist at UC San Francisco who has published extensively on DORA pharmacology, noted in a 2023 review: "Dual orexin receptor antagonists represent a mechanistically distinct option for insomnia that avoids the GABA-related risks of traditional hypnotics, but access barriers remain the primary obstacle for many patients" [11].

The Endocrine Society's 2020 guideline on sleep and metabolic health also states: "Clinicians should consider the cost-benefit profile of newer hypnotics, particularly in populations with comorbid metabolic disease where sleep quality directly impacts glycemic control" [12].

For Texas patients specifically, the gap between Medicaid non-coverage and the $85 average cash price creates a real affordability barrier. Until Texas Medicaid expands its insomnia formulary or suvorexant loses patent exclusivity (Merck's composition-of-matter patent expires in 2029), cost navigation will remain a necessary part of treatment planning. The recommended starting dose per the FDA-approved label is 10 mg taken within 30 minutes of bedtime, with at least 7 hours remaining before planned waking [5].